CURE Token Launches CURE Chain Development by Securing Technical Advisor Jim Nasr
Chicago, IL
|
February 15, 2022 10:00 AM Eastern Standard Time
Jacob Beckley, visionary founder of CURE Token and THE BECKLEY FOUNDATION philanthropist, has set his sights on another new and exciting venture in his quest to upend traditional approaches to medical research and to enable universal access to medical care, especially for the underserved. As COVID hampered the The Beckley Foundation's fundraising events and efforts, Beckley needed innovative, alternative ways to fund its commitments to active medical research programs. CURE Token was launched to fill funding gap, and instead exploded in a short time to a $52M market cap, enabling the expansion of the Beckley foundation's mission to include supplementing the devastating patient and family costs associated with childhood cancer care.
"Supporting childhood cancer research, patients and their families is a compassionate effort, and I'm pleased we are able to make even a small difference", says Beckley, "but it's the tip of an iceberg fraught with underlying problems in an industry disinterested in change". He goes on to describe two fundamental healthcare industry problems at opposite ends of the delivery system. "Researchers need to share data, every day, real-time, in an anonymous, secure system. COVID vaccines are an example of the speed and acuity that can be brought to bear through real-time collaboration. That same process needs to be replicated every day, in every way, on every research project. By the time professional papers are published and peer reviewed, it's already old news". At the other end of the spectrum Beckley talks about his primary goal: patient access. "All the medical research, innovation and development in the world is worthless if patients are unable to access it due to economics or geography. Healthcare access should not be limited to the wealthy, the insured, or the geographically well located. Healing is for everyone."
CURE Chain, Beckley's visionary concept to address both of these goals is becoming a reality, and he's harnessing the horsepower to make it happen sooner rather than later. Jim Nasr, a well-respected tech innovator and CEO of Acoer, an award-winning tech firm specializing in user friendly blockchain development will join Beckley in structuring and launching CURE Chain. Nasr is well versed in the healthcare industry, from his role as chief software architect for the Centers for Disease Control (CDC) in the US, his collaboration with Mayo Clinic's development of their connected diagnostics platform, and positions on a variety of key healthcare technology committees and related boards.
"CURE Chain provides a novel opportunity to address the issues that Jacob has identified. As example, through use of Non-Fungible Tokens (NFTs) on a public Distributed Ledger Technology (DLT) network, we intend to reference clinical research and patient data uniquely, securely and in a privacy preserving manner. This DLT “anchoring” will significantly increase confidence on the authenticity of the underlying data and accountable monitoring and usage it," says Nasr. “We firmly believe that properly conceived DLT and blockchain integration as an underlayer of computational trust can lead to decentralized healthcare delivery and the leveling of the playing field—reducing the gap between the developed and underdeveloped health systems, the insured and uninsured, and the wealthy and the poor."
Full CURE Chain implementation will proceed after the conclusion of the already underway key design activities. These include: Technical architecture design—on schedule, with the technical team already hard at work, identification of research organizations for piloting clinical trial data exchange, and the development of patient user experience models.
"Financial institutions tried to thwart cryptocurrency development and growth, but it happened anyway by mass demand. CURE Chain will change a healthcare industry that doesn't know it's broken and has no motivation to change, and it will do it by mass demand," Beckley explains. "Once it catches on and people, both researchers and patients, see the value change will be monumental". A pretty bold, futuristic statement, but it comes from someone whose title is "Senior Vice President of Innovation, Product and Technology" at one of the country's acclaimed digital innovation firms, Fusion92. Perhaps it's time to pay attention.
Contact Details
Eric Brown
+44 7960 044904
